A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars-Sinai researchers. Experts call it a game changer that’s likely to reshape treatment guidelines for aggressive prostate cancer.
A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars-Sinai researchers. Experts call it a game changer that’s likely to reshape treatment guidelines for aggressive prostate cancer. A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars-Sinai researchers. Experts call it a game changer that’s likely to reshape treatment guidelines for aggressive prostate cancer.